Claris Ventures Closes First Round of Claris Biotech II Fund at €100 Million
Funding | Apr 23, 2025 | CDP Venture Capital
Claris Ventures, in collaboration with CDP Venture Capital and FEI, has announced the first closing of their Claris Biotech II fund, which aims to accumulate €100 million. This venture capital fund is strategically positioned to support early-stage biotech startups within Italy, leveraging the local research and development ecosystem. This initiative underscores the commitment to fostering innovation across life sciences, encouraging economic growth and advancements in biotech sectors.
Sectors
- Venture Capital
- Biotechnology
- Life Sciences
Geography
- Italy – The article focuses on supporting biotech startups emerging from Italy's research ecosystem.
- Europe – FEI's involvement suggests a broader European interest in the biotech and life sciences sectors.
Industry
- Venture Capital – The article relates to venture capital, highlighting Claris Ventures' initiative to fund early-stage biotech companies.
- Biotechnology – This industry is relevant as the fund targets early-stage biotech startups, indicating a strong focus on life sciences and biotech innovation.
- Life Sciences – The fund's goal to promote innovation in life sciences situates this industry as central to the article's content.
Financials
- €100 million – The target amount for the Claris Biotech II fund focused on early-stage biotech startups.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Claris Ventures | Fund Manager | Company | Claris Ventures is leading the Claris Biotech II fund initiative focused on biotech startups. |
| CDP Venture Capital | Investor | Company | CDP Venture Capital is a backer of the Claris Biotech II fund, supporting innovation in life sciences. |
| FEI (European Investment Fund) | Investor | Company | FEI supports the fund, emphasizing a European commitment to biotech development. |